Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC has reduced its stake in Teva Pharmaceutical Industries by 17.2%, selling 36,574 shares during the first quarter, leaving them with 175,949 shares valued at $2.7 million.
• Several other institutional investors, including Golden State Wealth Management LLC and Brooklyn Investment Group, have also made moves in Teva's stock, with the latter increasing its stake by 403.4%.
• Analysts have a consensus rating of "Buy" for Teva's shares, with a price target of $24.71, despite UBS cutting their price objective from $24.00 to $23.00.

Voya Investment Management LLC trimmed its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 17.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 175,949 shares of the company's stock after selling 36,574 shares during the quarter. Voya Investment Management LLC's holdings in Teva Pharmaceutical Industries were worth $2,704,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Duquesne Family Office LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 65.4% in the 1st quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock worth $228,702,000 after acquiring an additional 5,882,350 shares during the last quarter. Amundi raised its position in Teva Pharmaceutical Industries by 18.5% in the 1st quarter. Amundi now owns 678,758 shares of the company's stock worth $10,080,000 after purchasing an additional 105,846 shares during the period. Jump Financial LLC lifted its stake in Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock worth $20,373,000 after purchasing an additional 838,423 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Teva Pharmaceutical Industries by 5.7% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock valued at $38,487,000 after buying an additional 134,705 shares during the period. Finally, Financial Sense Advisors Inc. grew its stake in shares of Teva Pharmaceutical Industries by 63.5% during the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock valued at $6,231,000 after buying an additional 157,421 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the company's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares of the company's stock, valued at approximately $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.52 during trading hours on Monday, reaching $18.87. 14,895,013 shares of the company's stock were exchanged, compared to its average volume of 11,941,043. The business has a fifty day moving average of $17.51 and a two-hundred day moving average of $16.59. The company has a market capitalization of $21.64 billion, a P/E ratio of -117.94, a price-to-earnings-growth ratio of 1.07 and a beta of 0.72. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. Teva Pharmaceutical Industries's quarterly revenue was up .3% on a year-over-year basis. During the same period in the previous year, the business posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on TEVA. UBS Group decreased their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 target price on the stock. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $24.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.